The #BigDataforBloodCancer Awareness Campaign is powered by the HARMONY Alliance in collaboration with the European Hematology Association (EHA).

#WorldCancerDay #CloseTheCareGap 

Selecting the best treatment for individual blood cancer patients

Using the power of Big Data to improve the treatment of blood cancers. That is our mission. We have developed the HARMONY Alliance Big Data Platform, which contains anonymized data sets from tens of thousands of European patients with blood cancer. Using this platform and innovative data analytic tools, our scientists are addressing pressing research questions. This results in evidence-based treatment choices that are tailored to the needs of individual patients. We have identified more than 165,000 patient data sets from 128 institutions across Europe, have a look at our data barometer >

Unraveling the biology of blood cancers

In the past seven years, HARMONY Alliance research teams have already answered critical research questions about blood cancers. Scan our examples below and check out our news page to learn more about these data-driven scientific results >

Acute Leukemias

Chronic Leukemias

Lymphomas and Myeloma

We have developed methods that can assist doctors. Tools to decide which patients should undergo intensive therapy and which can safely receive a milder treatment.

Listen to Natacha Bolanos of the Lymphoma Coalition

Listen to Jan Geissler of LeukaNet and CML Advocates Network

Sharing anonymized data in a secure way, for research purposes, is like a new form of blood donation in the era of digitalization and Big Data. In result, it has the power to save human lives

Who we are we
The HARMONY Alliance is a European Public-Private Partnership. We are funded by the Innovative Health Initiative (European Commission). Our partners are hospitals, research institutes, patient organizations, medical associations, pharmaceutical companies, IT companies, and regulatory/health technology assessment agencies. More than 128 organizations from 28 countries already share our mission to personalize treatments for blood cancer patients. 

Our research focus
We study all types of blood cancer, including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma (NHL), Pediatric Hematologic Malignancies, Myeloproliferative (MPN) disorders, and Chronic Myeloid Leukemia (CML). 

Listen to Amir Enshaei, of Newcastle University 

Patients involved
European patient organizations form the HARMONY Alliance Patient Cluster: Acute Leukemia Advocates Network (ALAN), CLL Advocates Network, CML Advocates Network, ChildhoodCancer/CCI Europe, Lymphoma Coalition, MDS Alliance, Myeloma Patients Europe and MPN Advocates Network. Our Patient Cluster representatives and their patient communities are involved in defining outcomes, designing research projects, and informing patients. 

Blood Cancer Awareness 

We are standing by patients with blood cancer and their families, especially during the special awareness activities conducted by many patient organisations all over the world. Despite more than a million people across the globe experiencing the pain of a blood cancer diagnosis every year, awareness of this disease is still low. Data-driven science will increase treatment efficacy, decrease adverse effects, prolong survival, and improve the quality of life of patients. In this way, we hope to contribute to reducing inequities in blood cancer care across the globe.

Listen to our valued HARMONY Alliance experts

Find us and follow us